Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Subscribe Listen in podnod RSS feed Show website

413 episodes
Updated Yesterday

Episodes413

Newest first

May 11 · 2 min
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ subsidiary to accelerate the launch of bepirovirsen, the FDA approves Bizengri under the Commissioner's National Priority Voucher program, and President Trump has signed off on a plan to fire FDA Commissioner Marty Makary.
May 8 · 2 min
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape the drug delivery device market, and experts discuss the key forces driving renewed growth in radiopharmaceuticals.
May 7 · 2 min
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24-week results from the Phase III TRuE-AD4 trial of Opzelura, and Pharmaceutical Executive speaks with Charlie Lyon of the API Innovation Center on what the conversation about bringing pharmaceutical manufacturing back to the United States is still missing.
May 6 · 9 min
Strengthening the Generic Drugs Supply Chain
Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.
May 6 · 3 min
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.
May 5 · 3 min
Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.
May 4 · 2 min
Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.
May 1 · 2 min
Pharmaceutical Executive Daily: FDA Approves Auvelity
In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.
April 30 · 2 min
Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO
In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.
April 29 · 3 min
Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher
In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.
April 28 · 2 min
Pharmaceutical Executive Daily: FDA Approves Breztri
In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.
April 27 · 3 min
Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia
In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene therapies toward commercial scale.
April 24 · 2 min
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.
April 23 · 2 min
Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.
April 23 · 8 min
The Ron Lanton Report: Where Innovations Happens
In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.
April 22 · 2 min
Pharmaceutical Executive Daily: Idvynso Receives FDA Approval
In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights which top-selling drugs are most at risk of supply shortages.
April 21 · 2 min
Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast
In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results, Pfizer works to reshape its leadership narrative as it approaches a major patent cliff, and a new industry perspective highlights why scaling artificial intelligence in pharma requires more than just advanced algorithms.
April 20 · 1 min
Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics
In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.
April 17 · 36 min
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential — and perhaps least understood — business challenge: revenue management. 01:50 - Drivers of rising GTN complexity. 05:08 - The Medicaid dilemma: Exiting the program. 08:30 - Coordination of benefits and rebate eligibility: “We’re doing a really poor job at this.” 10:57 - The easiest way to solve the problem. 12:04 - IRA’s Medicare drug price negotiations: Where we stand. 16:20 - Launch strategy and sequencing considerations. 20:13 - MFN agreements transparency. 21:51 - Data disconnect blurs pricing and revenue visibility. 24:05 - AI "catch-up" imperatives for revenue management. 27:48 - System strain? DTC’s downstream impacts. 33:36 - Top threats to future model.
April 16 · 2 min
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.